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Abstract
Background: Vascular cognitive impairment, no dementia (VCIND) refers to cognitive deficits associated with
underlying vascular causes that fall short of a dementia diagnosis. There is currently no treatment for VCIND.
Computerized cognitive training, which has significantly improved cognitive function in healthy older adults
and patients with cognitive impairment has not yet been applied to VCIND.
Methods/Design: The proposed study is a three-center, double-blinded, randomized controlled trial that will
include 60 patients with VCIND. The patients will be randomized to either a training or a control group. The
intervention is internet-based cognitive training performed for 30 min over 35 sessions. Neuropsychological
assessment and functional and structural MRI will be performed before and after 7 weeks training. Primary
outcomes are global cognitive function and executive function. Secondary outcome measures are neuroplasticity
changes measured by functional and structural MRI.
Discussion: Applying an internet-based, multi-domain, adaptive program, this study aims to assess whether
cognitive training improves cognitive abilities and neural plasticity in patients with subcortical VCIND. In addition
to the comprehensive assessment of the participants by neuropsychological tests, cerebrovascular risk factors
and apolipoprotein E genotyping, neuroplasticity will be used as an evaluation outcome in this study for, to our
knowledge, the first time. The combination of functional and structural MRI and neuropsychological tests will
have strong sensitivity in evaluating the effects of cognitive training and will also reveal the underlying mechanisms
at work.
Trial registration: ClinicalTrials.gov NCT02640716. Retrospectively registered on 21 December 2015.
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Background
Cerebrovascular disease remains the second leading con-
tributor to disability in older people in low- and middle-
income countries [1]. In addition to causing physical dis-
abilities, cerebrovascular disease has long been recog-
nized as an important cause of cognitive impairment.
The term ‘vascular cognitive impairment’ was introduced
to explain all forms of cognitive dysfunction caused by
cerebrovascular disease, ranging from mild cognitive
dysfunction (vascular cognitive impairment, no demen-
tia, VCIND) to overt dementia (vascular dementia) [2].
Vascular cognitive impairment, no dementia, which is
also termed mild vascular cognitive disorder [3], refers
to cognitive deficits associated with underlying vascular
causes that fall short of a diagnosis of dementia [4, 5].
According to the China Cognition and Aging Study,
VCIND is the most common subtype of mild cognitive
impairment in China, accounting for 42.0 % of the total
cases [6]. Fifty percent of patients with VCIND in the
Canadian Study of Health and Aging progressed to de-
mentia over 5 years of follow-up [7].
Although early intervention of VCIND holds the
potential to delay or even reverse cognitive impairment,
no treatment is available to prevent further decline in
patients with VCIND [8]. Because of the significant
heterogeneity of VCIND, clinical intervention trials need
to focus on a particular subtype to obtain an accurate
efficacy evaluation [8]. Owing to its relatively homoge-
neous features, VCIND caused by subcortical ischemic
small vessel disease (subcortical VCIND) is a suitable
category for intervention trials.
Executive dysfunction is the characteristic impairment
in subcortical vascular cognitive impairment [9–12]. This
is mainly due to disruption of the frontal-subcortical cir-
cuits, which are particularly vulnerable to ischemic lesions.
The occurrence of executive dysfunction also provides a
clue for cognitive training. Cognitive training refers to an
intervention that provides structured practice on tasks
relevant to different aspects of cognitive function, such as
memory and executive function. Training-related cogni-
tive improvements in healthy older people have been
found [13], with the effect being preserved 6 months after
training [14].
Similar training-related cognitive improvements have
also been observed in patients with cognitive impair-
ment [15–18] with a trend to apply multi-domain pro-
grams [19]. Those enhancements were preserved 6
months [20] and 28 months [21] after training. Although
inconsistencies have been found in behavioral or clinical
symptom evaluation [16], recent studies using functional
or structural MRI have more consistently shown neural
plasticity in patients with amnestic mild cognitive im-
pairment [22, 23]. To date, no cognitive intervention
study on VCIND has been published. Whether and how
cognitive training improves cognitive function in pa-
tients with VCIND remains largely unknown.
Brain structural and functional plasticity are the
underlying mechanism of cognitive training [24]. Struc-
tural plasticity included increased cortical thickness [25]
or improved white matter integrity [26]. Functional plas-
ticity included changes in brain function [14] or cerebral
blood flow [27]. This training-related neuroplasticity has
also been observed in patients with cognitive impair-
ment [22]. Therefore, in addition to unveiling the mech-
anism, neural plasticity change could also be used to
evaluate the efficacy of cognitive training.
This trial is the first study to test the efficacy of cogni-
tive training on VCIND using a double-blinded, ran-
domized controlled trial design. To evaluate the efficacy
of cognitive training, both traditional outcomes, such as
neuropsychological assessment, and neuroplasticity out-
comes, such as brain microstructure index, will be used.
Neuroplasticity outcomes might identify training-related
changes with more sensitivity. In addition, this study
seeks to investigate individual differences in training
outcome and its relationship with apolipoprotein E
genotyping and cerebrovascular risk factors.
Methods/Design
Study design
This study will be implemented as a three-center double-
blinded randomized trial. The study was registered under
clinicaltrials.gov (NCT02640716). This study will be re-
ported in accordance with both the CONSORT statement
and the CONSORT statement for non-pharmacological
interventions [28, 29].
The primary objective is to assess whether cognitive
training in patients with subcortical VCIND improves
their cognitive abilities. The second objective is to
evaluate the effect of cognitive training on neural
plasticity. Finally, possible genetic and plasma bio-
markers related to the effect of the training will be
examined.
Participants
Sixty patients with subcortical VCIND will be recruited
on fulfillment of the inclusion criteria. The patients will
be randomly allocated into the experimental group or
the control group. Patients will be recruited in neurology
clinics at Beijing Friendship Hospital, Xuan Wu Hos-
pital, and the geriatric clinic at Fu Xing Hospital, Capital
Medical University.
Inclusion criteria
 Literate Han Chinese, aged 50 years or older, with a
consistent caregiver who accompanies the subject at
least 4 days per week
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 Patient or informant report of cognitive impairment
involving memory or other cognitive domains
lasting for at least 3 months
 Neither normal nor demented according to the
criteria of the Diagnostic and Statistical Manual
of Mental Disorders, Fourth Edition [30, 31], with
a Clinical Dementia Rating ≥0.5 on at least one
domain [32] and a global score ≤0.5; a Mini-Mental
State Examination score ≥20 (primary school),
or ≥24 (junior school or above) [33, 34]
 Normal or slightly impaired activities of daily
living as defined by a total score of ≤1.5 on the
three functional Clinical Dementia Rating domains
(home and hobbies, community affairs, and
personal care) [34]
 MRI entry criteria:
o At least three supratentorial subcortical small
infarcts (3–20 mm in diameter), with or without
white matter lesions of any degree; or moderate
to severe white matter lesions (score ≥2
according to the Fazekas rating scale) [35] with
or without small infarcts
o Absence of cortical and watershed infarcts,
hemorrhages, hydrocephalus, and white matter
lesions with specific causes (e.g., multiple
sclerosis)
o No hippocampal or entorhinal cortex atrophy
(score 0 according to the medial temporal lobe
atrophy scale of Scheltens) [36]
Exclusion criteria
 Severe aphasia, physical disabilities, or any other
factor that might preclude completion of
neuropsychological testing
 Clinically significant gastrointestinal, renal, hepatic,
respiratory, infectious, endocrine, or cardiovascular
system disease; cancer; alcoholism; drug addiction
 Disorders other than subcortical VCIND that
might affect cognition; a Hamilton Depression Scale
score >17 or schizophrenia; new strokes within 3
months before baseline; inherited or inflammatory
small vessel disease
 Use of medications that may affect cognitive
functioning, including tranquilizers, anti-anxiolytics,
hypnotics, nootropics, and cholinomimetic agents;
and inability to undergo brain MRI
Randomization
Participants will be randomly allocated to either the
intervention group or the control group in a ratio of 1:1.
After participants have given their informed consent,
randomization will be performed by an independent
statistician who is blinded to the patient interventions
using simple randomization of random number table
method in SAS software (SAS Institute, Inc., Cary, NC,
USA). Afterwards, the sealed randomization codes and
intervention number are sent out to each center. Blind-
ing will be broken only if a participant needs emergency
treatment. Once the blinding is broken, the participant
will be managed as off-trial.
Blinding
Patients, caregivers, radiologists, statisticians, and neuro-
psychologists who measure the outcomes will be blinded
to the randomization status. Blinding will also be main-
tained for data management, outcome assessment, and
data analysis.
Intervention
Previous studies showed that training approaches with
multi-domain, personalized, and adaptive training
features are more effective [19, 37, 38]. Therefore, cogni-
tive training will be a computerized multi-domain adap-
tive training program in this trial. Training paradigms
that were successfully used in previous studies will be
adopted [19, 37], including processing speed, attention,
long-term memory, working memory, flexibility, calcula-
tion, and problem solving. Specific training paradigms
include a time perception task, visual search task, rapid
serial presentation task, delayed match to sample task,
paired-associate recall task, attention span task, digit
span task, go–no go task, Stroop task, task switching,
and n-back working memory task. To enable adaptive
training, each task was designed with several difficulty
levels. Based on previous tests with a large size sample,
the tasks will be further grouped in each domain with
varied task difficulty. At the beginning, assignment tasks
from these domains will be similar across participants.
On each training day, five tasks (2 min per task, each
three times, in total 30 min per day) will be assigned.
Within each task, high accuracy (>80 %) is required to
upgrade. To manipulate the adaptive change, the num-
ber of types of stimuli, the presentation probability of
each type of stimuli, and the size and duration of a
stimulus were systematically set. To keep a systematical
setting, only one parameter will be changed, while the
other parameters will be kept as constant in one level
upgraded. Once the task performance is higher than
80 % of the norm performance of a normal aging
population, the task will be replaced by a harder task
from the same domain. The training is thus also
adaptive at participant level, with a similar setup but
personalized progress across participants.
For the control group, processing speed and attention
tasks are included, with five tasks and 30 min training in
each day. Importantly, a fixed, primary difficulty level for
all participants in the control group is set. The training
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will be completed at home and supervised by an inde-
pendent neurologist over the internet (www.66nao.com).
Primary outcome measures
The primary outcome measures are global cognitive func-
tion measured by the Montreal Cognitive Assessment and
executive function measured by the Trail Making Test B-A.
Secondary outcome measures
The secondary outcome measure is neuroplasticity
changes, as measured by MRI. Specifically, the brain
functional response, including regional activation
magnitude and functional connectivity across regions
will be assessed. For fMRI, both before and after the
trial, a resting state scan, a scan with a cognitive con-
trol task, and a scan with an episodic memory task
will be included. The brain response change during
the tasks and functional connectivity across regions in
the task and the resting state sessions will be exam-
ined between groups. The structural change, including
gray matter volume, measured by voxel-based mor-
phometrics, and white matter microstructure, mea-
sured by diffusion tensor imaging, will be assessed.
Data collection
At screening, the following data will be collected: demo-
graphic data (sex, age, education, and occupation); med-
ical history; concomitant medications; findings from a
complete physical examination and neurological examin-
ation; neuropsychological assessment; blood analysis;
inclusion and exclusion criteria will be assessed; func-
tional and structural brain MRI will be carried out if the
patient meets the inclusion and exclusion criteria.
Blood samples will be collected and the following tests
will be carried out: complete blood count, liver enzymes,
kidney function, blood glucose, cholesterol, homocyst-
eine, and apolipoprotein E genotyping.
A follow-up assessment will be scheduled after 7
weeks of cognitive training. Data from the following ex-
aminations will be collected: physical and neurological
examinations; neuropsychological assessment; functional
and structural brain MRI (Fig. 1).
Neuropsychological assessment
The neuropsychological evaluation includes the adminis-
tration of several commonly used measures (tests,
interview, and questionnaires) of cognitive and daily
functions. Measures include the Mini-Mental State
Examination, the Montreal Cognitive Assessment, the
Clinical Dementia Rating scales, Digit Span, Trail
Making Test A and B, the WHO-UCLA Auditory Verbal
Learning Test, the Boston Naming Test, the Hachinski
Ischemic Scale, the Geriatric Depression Scale, the
Neuropsychiatric Inventory, and an activities of daily
living assessment. Furthermore, in the executive domain,
a task-switching paradigm that includes non-switch and
switch blocks will be administered inside the scanner. In
the memory domain, an episodic memory task that
includes a learning session and a test session will be ad-
ministered both outside and inside the scanner.
MRI protocol
Patients will undergo brain MRI at baseline and 7 weeks
after training. The brain MRI will be performed using an
optimized protocol, with the same 3 T MRI scanner
(Magnetom Skyra, Siemens Healthcare, Erlangen,
Germany). Following a pilot scan, a three-dimensional
magnetization-prepared rapid gradient-echo scan will
be performed (repetition time = 1690 ms, echo time =
2.56 ms, flip angle = 12°, 1 mm isotropic voxels cover-
ing the whole brain). T2*-weighted functional images
will be collected using a gradient-echo echo-planar
imaging sequence (33 interleaved slices, repetition
time = 2000 ms, echo time = 30 ms, flip angle = 83°,
field of view = 224 mm2, matrix = 64 × 64, 3.5 mm iso-
tropic voxels). Diffusion tensor imaging will use a
double spin-echo echo-planar imaging sequence
(repetition time = 8000 ms, echo time = 96 ms, flip
angle = 90°, field of view = 224 mm2, in-plane reso-
lution =1.75 × 1.75 mm voxels, 54 contiguous 2 mm
thick axial slices). Diffusion tensor images will be ac-
quired with 64 noncollinear encoding directions (b =
1000 s/mm2) and 11 images without diffusion weight-
ing (b = 0 s/mm2, b0). All scans will be reviewed quali-
tatively by a radiologist to screen for possible brain
lesions or structural abnormalities. Diffusion tensor
Fig. 1 Overview of the flow of participants through the trial
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imaging and functional MRI data collected during the
episodic memory task will be analyzed using the FSL
package (FMRIB Analysis Group, Oxford, UK). Brain
activation and connectivity changes before and after
training will be compared between experimental and
control groups. By using tract-based spatial statistics
implanted in FSL, fractional anisotropy and mean dif-
fusivity values in central white matter tracts will be
measured and compared before and after training.
Apolipoprotein E genotyping
High-molecular-weight DNA will be isolated from per-
ipheral blood leukocytes using a QIAamp DNA Blood
Kit (QIAGEN, Valencia, CA, USA). Genomic DNA will
be amplified by PCR using the primers ApoE-5′: 5′-
AGACGCGGGCACGGCTGTCCAAGGA-3′ and ApoE-
3′: 5′-CCCTCGCGGGCCCCGGCCTGGTACAC-3′ with
the following conditions: denaturation at 95 °C for 5 mi-
nutes, followed by 30 cycles at 95 °C for 30 s, annealing at
60 °C for 30 s, and extending at 72 °C for 30 s. The PCR
products will be digested with HhaI (R0139S, New Eng-
land BioLabs, Beverly, MA, USA). The fragments will be
separated by electrophoresis on a 20 % polyacrylamide gel
and visualized using GelGreen™ nucleic acid gel stain
(89139–144, Biotium, Hayward, CA, USA).
Data monitoring
All participants from three centers will be evaluated by
the same trained neuropsychologists and undergo brain
MRI using the same MRI scanner. Imaging data are
checked for quality and protocol conformity after each
scanning session.
Sample size estimates
In preliminary tests, the observed mean difference in
change from baseline in the DST, WHO-UCLA Auditory
Verbal Learning Test, and Boston Naming Test scores
between training and control groups were 14.92, 3.35,
and 7.59, respectively, and the standard deviations were
18.41, 4.05, and 9.06, respectively. Based on these data,
sample sizes of 48, 46, and 46, respectively, were needed
to obtain a statistical power of 80 % with a significance
level of 5 %. We used the largest sample size of 48, and
the inclusion number has been set to 60 patients, allow-
ing for a maximum dropout rate of 20 %. Power calcula-
tions are based on the primary outcome measures,
which are assessed by neuropsychological tests. The stat-
istical power measures will be calculated using the
POWER procedure in SAS® Version 9.3.
Statistical analysis
Performance changes in the assessment scores related to
global cognitive function (Montreal Cognitive Assessment)
and executive function (Trail Making Test B-A) are the
primary outcome measures of interest. An independent-
sample t test will be used separately for the assessment
criterion and the rating scales of function, to ensure that
baseline levels are comparable between the training and
control groups. A paired-samples t test will be conducted
to compare the changes in scores in the trained tasks to
investigate the training efficacy. The performance change
of the trained tasks will be further correlated with the
neuropsychological change. To test whether the training
will improve neuropsychological performance in the con-
trol group, correlation analysis will be conducted between
the performance of trained tasks and the neuropsycho-
logical change. To determine the training transfer effect, a
series of 2 × 2 ANOVAs will be conducted with group and
time points as the two factors. For all analyses, signifi-
cance levels will be set to 0.05, and effect sizes refer to
partial η-square values. Statistical analysis will be con-
ducted using SPSS20.0 software. Imaging data will be ana-
lyzed using FSL to detect any changes in brain function
and structure due to cognitive training.
Discussion
To our knowledge, this trial is the first to evaluate the cogni-
tive training efficacy in VCIND patients. This study has
several strengths. First, the multi-domain cognitive training
applied in this study is highly adaptive and internet-based.
Such training is believed to be effective in enhancing cogni-
tive function. Conducting training on the internet is conveni-
ent, allowing patients to train at home and doctors to easily
manage the training protocol and monitor training progress.
Second, functional and structural plasticity are used as
the evaluation outcome measures. Compared with the
traditional efficacy evaluations, which use neuropsycho-
logical tests, the combination of neuroplasticity and
neuropsychological tests in this study will be more sensi-
tive in testing cognitive training efficacy, because smaller
training effects could be detected by MRI indices, such as
brain activity and connectivity [16]. In this trial, by includ-
ing the functional and structural MRI measurements, a
further purpose is to reveal the underlying mechanism at
work. For instance, fMRI measurement would provide evi-
dence to distinguish whether neural efficiency was im-
proved or the brain function was reorganized to achieve
cognitive enhancement. The structural MRI measurement
would provide evidence on the structural constraint on
functional change due to cognitive training.
Another strength of this trial is the comprehensive
assessment of the participants on multiple levels, includ-
ing neuropsychological tests, neuroplasticity analysis,
cerebrovascular risk factors, and apolipoprotein E geno-
typing. This comprehensive assessment will be able to
identify possible biomarkers involved in the effects of
cognitive training in VCIND.
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Trial status
This trial is currently recruiting participants.
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